Minutes of the CVMP meeting 10-12 February 2026

Human medicines European public assessment report (EPAR): Besremi, ropeginterferon alfa-2b, Date of authorisation: 15/02/2019, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 15, Status: Authorised

Orientation guide for patient representatives and healthcare professionals - EMA building

Orientation guide for delegates - EMA building

Human medicines European public assessment report (EPAR): Advate, octocog alfa, Date of authorisation: 02/03/2004, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Caelyx pegylated liposomal, doxorubicin, Date of authorisation: 20/06/1996, Revision: 40, Status: Authorised

Human medicines European public assessment report (EPAR): Striascan, ioflupane (123l), Date of authorisation: 25/06/2019, Revision: 5, Status: Authorised

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2026

Human medicines European public assessment report (EPAR): Viokat, diazoxide choline, Status: Application withdrawn